Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for untreated advanced or recurrent non-small cell lung cancer (NSCLC) when platinum-doublet chemotherapy is unsuitable.
The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. In light of the update from the company that market Atezolizumab, NICE will now stop the scoping exercise. Please accept our apologies for any inconvenience.
 
Status Suspended
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6218

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
20 May 2024 Suspended. The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. In light of the update from the company that market Atezolizumab, NICE will now stop the scoping exercise. Please accept our apologies for any inconvenience.
22 March 2024 - 09 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6218
22 March 2024 In progress. Scoping commencing
22 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual